On Jul. 7, 2022, Novavax announced that the European Commission had approved a variation to allow SK bioscience to manufacture and supply the active substance in the Nuvaxovid (NVX-CoV2373) COVID-19 vaccine to the European Union. This variation approval enabled Novavax to manufacture product for the EU from two major vaccine suppliers – SK bioscience and the Serum Institute of India.

SK bioscience currently manufactures drug substance and drug product of Nuvaxovid for the South Korean market and will now manufacture drug substance for the EU as well.